Evidence map›Paper›PMID 24586188›Full record

ArticlePLoS genetics2014

Serine carboxypeptidase SCPEP1 and Cathepsin A play complementary roles in regulation of vasoconstriction via inactivation of endothelin-1.

Xuefang Pan, Lubov Grigoryeva, Volkan Seyrantepe, Junzheng Peng, Katrin Kollmann, Johanne Tremblay, Julie L Lavoie, Aleksander Hinek, Torben Lübke, Alexey V Pshezhetsky

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Xuefang PanDepartment of Medical Genetics, CHU Sainte-Justine Research Center, University of Montreal, Montreal, Canada.
Lubov GrigoryevaDepartment of Medical Genetics, CHU Sainte-Justine Research Center, University of Montreal, Montreal, Canada.
Volkan SeyrantepeIzmir Institute of Technology, Department of Molecular Biology and Genetics, Urla Izmir, Turkey.
Junzheng PengCHUM Research Center and the Department of Kinesiology, University of Montreal, Montreal, Canada.
Katrin KollmannDepartment of Biochemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Johanne TremblayCHUM Research Center and the Department of Kinesiology, University of Montreal, Montreal, Canada.
Julie L LavoieCHUM Research Center and the Department of Kinesiology, University of Montreal, Montreal, Canada.
Aleksander HinekCardiovascular Research Program, The Hospital for Sick Children, University of Toronto, Toronto, Canada.
Torben LübkeDepartment of Chemistry, Biochemistry I, Bielefeld University, Bielefeld, Germany.
Alexey V PshezhetskyDepartment of Medical Genetics, CHU Sainte-Justine Research Center, University of Montreal, Montreal, Canada ; Department of Anatomy and Cell Biology, McGill University, Montreal, Canada.
Université de Montréal · CABielefeld University · DECentre Hospitalier Universitaire Sainte-Justine · CAIzmir Institute of Technology · TRMcGill University · CAUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potent vasoconstrictor peptides, endothelin 1 (ET-1) and angiotensin II control adaptation of blood vessels to fluctuations of blood pressure. Previously we have shown that the circulating level of ET-1 is regulated through its proteolytic cleavage by secreted serine carboxypeptidase, cathepsin A (CathA). However, genetically-modified mouse expressing catalytically inactive CathA S190A mutant retained about 10-15% of the carboxypeptidase activity against ET-1 in its tissues suggesting a presence of parallel/redundant catabolic pathway(s). In the current work we provide direct evidence that the enzyme, which complements CathA action towards ET-1 is a retinoid-inducible lysosomal serine carboxypeptidase 1 (Scpep1), a CathA homolog with previously unknown biological function. We generated a mouse strain devoid of both CathA and Scpep1 activities (DD mice) and found that in response to high-salt diet and systemic injections of ET-1 these animals showed significantly increased blood pressure as compared to wild type mice or those with single deficiencies of CathA or Scpep1. We also found that the reactivity of mesenteric arteries from DD mice towards ET-1 was significantly higher than that for all other groups of mice. The DD mice had a reduced degradation rate of ET-1 in the blood whereas their cultured arterial vascular smooth muscle cells showed increased ET-1-dependent phosphorylation of myosin light chain 2. Together, our results define the biological role of mammalian serine carboxypeptidase Scpep1 and suggest that Scpep1 and CathA together participate in the control of ET-1 regulation of vascular tone and hemodynamics.

Indexed as

Angiotensin IIAnimalsBlood PressureCarboxypeptidasesCathepsin ACells, CulturedEndothelin-1HemodynamicsHumansHypertensionMiceVasoconstrictionAngiotensin IICarboxypeptidasesCathepsin AEndothelin-1SCPEP1 protein, human

Identifiers

PMID24586188
PMCPMC3937211
OpenAlexW2081424390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.